Center for Oncological Research, University of Antwerp, Antwerp, Belgium; Department of Pathology, Antwerp University Hospital, Antwerp, Belgium; Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands.
Department of Pneumology, AZ Herentals, Herentals, Belgium.
Clin Lung Cancer. 2018 Jan;19(1):35-41. doi: 10.1016/j.cllc.2017.06.010. Epub 2017 Jul 6.
Several oncogenic drivers have been identified in non-small cell lung cancer. Targeted therapies for these aberrations have already been successfully developed and implemented in clinical practice. Owing to improved sensitivity in genetic testing, more and more tumors with multiple driver mutations are identified, resulting in dilemmas for treating physicians whether and which targeted therapy to use. In this case series, we provide an overview of patients with intrinsic double mutations in oncogenic drivers and their reported response to targeted therapies, with a focus on epidermal growth factor receptor, anaplastic lymphoma kinase, cMET, and Kirsten rat sarcoma viral oncogene. We also include an unpublished case report on a patient with an epidermal growth factor receptor L858R and cMET exon 14 skipping.
已经确定了非小细胞肺癌中的多个致癌驱动因素。针对这些异常的靶向治疗已经在临床实践中成功开发和实施。由于基因检测敏感性的提高，越来越多的肿瘤被发现具有多种驱动突变，这给治疗医生带来了是否以及使用哪种靶向治疗的难题。在本病例系列中，我们概述了具有内在双突变的致癌驱动因素的患者及其报告的对靶向治疗的反应，重点介绍了表皮生长因子受体、间变性淋巴瘤激酶、cMET 和 Kirsten 大鼠肉瘤病毒致癌基因。我们还包括了一份关于一名患者的表皮生长因子受体 L858R 和 cMET 外显子 14 跳跃的未发表病例报告。
